AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Development efforts refocused on pathogen inactivation, vaccines.
2003 NOV 12 - (NewsRx.com & NewsRx.net) -- Cerus Corporation (CERS) announced that the company is restructuring its operations to focus on its pathogen inactivation products for platelets and plasma and on its pipeline of therapeutics and vaccines.
The company will reduce operating expenses primarily related to its red blood cell program while it investigates alternative approaches to advance that program. The company previously announced termination of phase III clinical investigation of pathogen inactivated red blood cells.
As a result of the restructuring, the company will reduce its current workforce by approximately 25% and expects to reduce its research and development expenses for 2003 to approximately $55 million, from previously projected expenditures of $60-65 million. The change in focus is expected to result in an overall expense reduction of $20-25 million in 2004 over 2003.
"We are working expeditiously to cut expenses relating to the red blood cell clinical program," said Stephen T. Isaacs, president and chief executive officer. "Meanwhile, we are working with Baxter to commercialize Intercept Platelets in Europe and to complete the regulatory process for the product in the United States. In ...
- Cerus Obtains Exclusive Rights to INTERCEPT Blood System from Baxter.
- Press release article from: PR Newswire February 13, 2006 700+ words
...exclusive rights to the INTERCEPT Blood System for all three commonly transfused...of blood safety with the INTERCEPT Blood System," said Claes Glassell...successfully commercializing the INTERCEPT Blood System." "We believe that Cerus...
- INTERCEPT Blood System Received TE[pounds sterling]V Approval for Storage of...
- Press release article from: PR Newswire Europe September 22, 2005 700+ words
...major achievement for the INTERCEPT Blood System that represents an important...Baxter. In addition, the INTERCEPT Blood System provides enhanced patient...days. Furthermore, the INTERCEPT Blood System also allows for earlier...
- Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of...
- Newspaper article from: Blood Weekly August 28, 2008 700+ words
...allowing the use of its INTERCEPT Blood System(TM) to treat previously...mark registration for the INTERCEPT Blood System for platelets in 2002 and...expanding the scope of the INTERCEPT Blood System for use in various types...
- Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of...
- Press release article from: Business Wire August 12, 2008 700+ words
...allowing the use of its INTERCEPT Blood System(TM) to treat previously...mark registration for the INTERCEPT Blood System for platelets in 2002 and...expanding the scope of the INTERCEPT Blood System for use in various types...
- Cerus and Grifols Extend INTERCEPT Blood System Distribution to Italy.
- Newspaper article from: Blood Weekly June 11, 2009 700+ words
...territory to include Italy. The INTERCEPT Blood System inactivates a broad range...deploy and support the INTERCEPT Blood System in Italy. In 2007, the...annually for transfusion. The INTERCEPT Blood System will add state-of-the...
- Baxter and Cerus Sign New Agreement to Commercialize INTERCEPT Blood System.
- Press release article from: Business Wire February 3, 2005 700+ words
...collaboration related to the INTERCEPT Blood System. Under the agreement...to market and develop the INTERCEPT Blood System for platelets and plasma...each partner related to the INTERCEPT Blood System for plasma and red blood...
- Cerus' INTERCEPT Blood System Receives First Approval in Germany.
- Press release article from: Business Wire January 29, 2007 700+ words
...platelets treated with the INTERCEPT Blood System by a German blood center...center contained data on the INTERCEPT Blood System that can be used as a common...Cerus in commercializing the INTERCEPT blood system in Germany, the largest...
- Cerus Corporation Announces European Regulatory Approval for the INTERCEPT...
- Press release article from: Business Wire November 21, 2006 700+ words
...mark certificate for the INTERCEPT Blood System for plasma. This allows...allowing Cerus to sell the INTERCEPT Blood System for platelets and plasma...commercial product to our INTERCEPT Blood System product family. This marks...
Source: HighBeam Research, Development efforts refocused on pathogen inactivation, vaccines.